Abarceo Pharma AB
559139-7160ActiveDeveloping novel small molecule therapeutics targeting VDAC1 for diabetes.
Biotechnology Companyabarceo.com
Oversikt
- 5–9
- Ansatte
- 2.5–5mill SEK
- Omsetning
- 2017
- Grunnlagt
Nøkkelbeslutningstakere
Mozhgan Dorkhan
Consulting CMO
Adam Bruce
CEO
Claes Post
Board Member
Claes Wollheim
CSO & Scientific Founder
+11 flere kontakter i Funnelfeedr
Beskrivelse
Abarceo Pharma is a pre-clinical stage biotechnology company founded in 2017 as a spin-out from the Lund University Diabetes Center. It was established by world-renowned scientists specializing in diabetes research and beta-cell biology. The company has identified Voltage-Dependent Anion Channel 1 (...